<DOC>
	<DOC>NCT02876796</DOC>
	<brief_summary>The primary objective of this study is to assess the pharmacodynamic (PD) effects of GS-0976 (NDI-010976) on fractional de novo lipogenesis (DNL) following a single oral dose administration in overweight and/or obese, but otherwise healthy, male adults.</brief_summary>
	<brief_title>Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Overweight and/or obese, but otherwise healthy males Weight â‰¥ 50.0 kg Body Mass Index (BMI): 25.0 32.0 kg/m^2, inclusive Intolerance to or malabsorption of fructose A history of clinically significant gastrointestinal disease and/or surgery, which would result in the subject's inability to absorb or metabolize the study drug (e.g., gastrectomy, gastric bypass, cholecystectomy). In the opinion of the Investigator, a history of clinically significant hematologic, renal, hepatic, bronchopulmonary, neurological, psychiatric, metabolic , endocrine disorder (e.g., diabetes, thyroid disease), or cardiovascular disease.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>fractional de novo lipogenesis</keyword>
	<keyword>DNL</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>